The convergence of computer-aided drug design (CADD) with AI/ML, and agentic workflows is reshaping the landscape of biopharmaceutical R&D. By integrating biochemistry, molecular modeling, and the use of agentic AI for literature review, target discovery, and in silico screening, researchers can now explore molecular interactions and predict drug behavior, ultimately accelerating and reducing development costs.
In this session, you’ll learn how to:
Harness Rescale’s high performance computing (HPC) platform on AWS and gain instant access to the latest NVIDIA technologies, purpose-built for the demands of modern drug discovery.
Simplify the creation of next-generation drug discovery pipelines using AI-enhanced tools on AWS and NVIDIA.
Build AI agents that act as co-pilots for drug discovery scientists performing complex hypothesis building, literature review, and tool-calling.
Optimize and scale complex computational workloads—from molecular simulations to predictive modeling and data analysis.
Leverage AI frameworks to streamline model development, automate routine tasks, minimize duplications, and more.